Status:
COMPLETED
Detection and Characterization of Residual Masses in Lymphomas
Lead Sponsor:
The Lymphoma Academic Research Organisation
Conditions:
Hodgkin Lymphoma
B-Cell Lymphoma
Eligibility:
All Genders
18-80 years
Brief Summary
The present study aims to further optimize a whole-body Diffusion-Weighted Magnetic Resonance Imagery (DW-MRI or DWI) protocol on 3 Tesla MR and/or new system combining 3Tesla MR and Positron Emission...
Detailed Description
Imaging biomarkers are important tools for the detection and characterization of cancers as well as for monitoring the response to therapy. "Whole-body" molecular imaging, in particular using 18-Fluor...
Eligibility Criteria
Inclusion
- Newly diagnosed hodgkin's lymphoma, diffuse large B-cell lymphoma or follicular lymphoma
- Patients aged over 18
- Initial presentation of bulky disease
Exclusion
- Patients with impaired central nervous system
- Patients regularly taking corticosteroids during the 4 weeks preceding the treatment (unless the dose administered is equivalent to ≤20 mg/day prednisone).
- Patients who have undergone major surgery during the 28 days preceding the inclusion
- Patients with low kidney and/or liver function
- Patients with HIV +
- Patients whose life expectancy ≤ 6 months
- Patients with other medical problems or psychological susceptibles interfere with the study,
- Patients under adult supervision.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT02300402
Start Date
October 1 2014
End Date
December 1 2022
Last Update
March 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hopital Henri Mondor
Créteil, France, 94010